Table 4.

Disposition of polymorphisms involved in nevirapine metabolism

	Total	Hepatotoxicity	No hepatotoxicity	p*
	n = 362	n = 8	n = 354
ABCB1 c.3435/rs1045642, n (%)				0.019
CC	86 (23.8)	5 (5.8)	81 (94.2)
CT	178 (49.2)	1 (0.6)	177 (99.4)
TT	98 (27.0)	2 (2.0)	96 (98.0)
CYP2B6 c.516/rs3745274, n (%)				0.706
GG	196 (54.1)	6 (3.1)	190 (96.9)
GT	141 (39.0)	2 (1.4)	139 (98.6)
TT	25 (6.9)	0 (0.0)	25 (100.0)
CYP3A4/A5 **, n (%)				0.602
Extensive	58 (16.1)	0 (0.0)	58 (100.0)
Intermediate	270 (74.5)	8 (3.0)	262 (97.0)
Poor	25 (6.9)	0 (0.0)	25 (100.0)
nd	9 (2.5)	0 (0.0)	9 (100.0)

Abbreviations: n number, nd not determined, ABCB ATP Binding Cassette Subfamily B, CYP Cytochrome P450 enzyme

*χ2 test ** CYP3A4*22/rs35599367 and CYP3A5*3/rs776746 combined genotypes for comprehensive functional evaluation [33, 34]